Premium
Effects of inhaled corticosteroids and inhaled cromolyn sodium on urinary growth hormone excretion in asthmatic children
Author(s) -
Soferman Ruth,
Sapir Nurit,
Spirer Zvi,
Golander Avraham
Publication year - 1998
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/(sici)1099-0496(199811)26:5<339::aid-ppul6>3.0.co;2-g
Subject(s) - medicine , cromolyn sodium , asthma , budesonide , corticosteroid , inhaled corticosteroids , urinary system , excretion , inhalation , endocrinology , anesthesia
Over the past few years there has been an increasing awareness that asthma is a chronic inflammatory airways disease. The current therapeutic strategies for treating asthma focus on suppressing the inflammatory process by using cromones or inhaled corticosteroids (ICS). The beneficial effects of ICS in asthma are now well known, but its detrimental effect on linear growth remains a controversial issue. The aim of this open label, nonrandomized, cross‐sectional, one‐time study was to determine the influence of these drugs on urinary growth hormone (U‐GH) levels in prepubertal asthmatic children. U‐GH levels were measured in 47 prepubertal asthmatic children who had been treated for at least 6 months with either ICS (beclomethasone or budesonide at a mean daily dose of 360 μg) or with 80 mg daily dose of cromolyn sodium (CrS). There were also nine healthy children who served as a control. These three groups of children were matched for age and gender ratio. The mean level of U‐GH in the CrS‐treated group was 2.94 ± 0.96 ng/night; this was significantly higher compared to the mean level of the ICS‐treated group (1.99 ± 0.83 ng/night; P < 0.001) and to the mean level of the control group (1.98 ± 0.39 ng/night; P < 0.006). There was no significant difference between the mean level of U‐GH in the group treated by ICS and the controls ( P < 0.9). These results show that the mean levels of U‐GH secretion of the children who were treated by CrS for 6 months was significantly increased, compared to the mean U‐GH level of the ICS‐treated group and the controls. The mean U‐GH levels in the last two groups showed no statistically significant difference. Pediatr Pulmonol. 1998; 26:339–343. © 1998 Wiley‐Liss, Inc.